Immuno-Analyse & Biologie Specialisee最新文献_第2页

Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment? 肿瘤相关碳水化合物的模拟:它是癌症治疗的一个有希望的选择吗?

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-03-23 DOI: 10.3390/immuno3020009

V. Segatori, Gretel M. Ferreira, S. Rojo, Aylen Camila Nogueira, Jeremías Omar Castillo, Cynthia Antonella Gulino, M. Gabri

{"title":"Mimicry of Tumour-Associated Carbohydrates: Is It a Promising Option for Cancer Treatment?","authors":"V. Segatori, Gretel M. Ferreira, S. Rojo, Aylen Camila Nogueira, Jeremías Omar Castillo, Cynthia Antonella Gulino, M. Gabri","doi":"10.3390/immuno3020009","DOIUrl":"https://doi.org/10.3390/immuno3020009","url":null,"abstract":"Modulation of the immune system has been demonstrated as a powerful approach to treating cancer. Immunotherapies are generally classified as active or passive according to their ability to trigger the immune system. During the last decades, information regarding the relevance of aberrant glycosylation as a major player in tumour biology encouraged expectations for the development of new therapeutic strategies directed at glycans. Several tumour-associated carbohydrate antigens (TACAs) have been identified and validated as suitable immunotherapeutic targets, leading to promising therapeutic developments. It is known that TACAs are poorly immunogenic since they are unable to trigger a proper immune response. Given that they are not presented by major histocompatibility complex (MHC) molecules and that they induce immune tolerance, the development of active immunotherapeutic strategies against TACAs is a real challenge. However, antitumor strategies based on mimetics of TACAs have been developed and show promising results. Active immunotherapies based on TACAs mimicry can currently be grouped into strategies based on the use of mimetic peptides and anti-idiotype (Id) antibodies. In this review, we discussed the scientific basis on which these strategies are based and the available therapeutic options that have shown the best results in preclinical studies and in clinical practice.","PeriodicalId":55599,"journal":{"name":"Immuno-Analyse & Biologie Specialisee","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84181278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNA Let-7 Plays an Important Role in the Immunopathology of COVID-19: A Systematic Review MicroRNA Let-7在COVID-19免疫病理中发挥重要作用:系统综述

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-03-22 DOI: 10.3390/immuno3010008

Renato Luís Pessôa, Gustavo da Rosa Abreu, R. B. de Oliveira

{"title":"MicroRNA Let-7 Plays an Important Role in the Immunopathology of COVID-19: A Systematic Review","authors":"Renato Luís Pessôa, Gustavo da Rosa Abreu, R. B. de Oliveira","doi":"10.3390/immuno3010008","DOIUrl":"https://doi.org/10.3390/immuno3010008","url":null,"abstract":"COVID-19 has presented itself as a challenging task to medical teams and researchers throughout the world, since the outbreak of SARS-CoV-2 started in the Chinese city of Wuhan. To this day, there are still new variants emerging, and the knowledge about the mechanisms used by the virus to infect cells and perpetuate itself are still not well understood. The scientific community is still trying to catch up with the velocity of new variants and, consequently, the new physiological pathways that appear along with it. It is known that the new coronavirus plays a role in changing many molecular pathways to take control of the infected cells. Many of these pathways are related to control genomic expression of certain genes by epigenetic ways, allowing the virus to modulate immune responses and cytokines production. The let-7 family of microRNAs, for instance, are known to promote increased viral fusion in the target cell through a mechanism involving the transmembrane serine protease 2 (TMPRSS2). It was also demonstrated they are able to increase the inflammatory activity through the NF-κB/IL-6/let-7/LIN-28 axis. In addition, let-7 overexpression led to a reduction in inflammatory cytokines and chemokines expression (IL-6, IL-8 and TNF-α). Interestingly, the cytokines modulated by the let-7 family are related to COVID-19-induced cytokine storm observed in patients undergoing clinical phase three. Thus, let-7 can be considered a novel and attractive biomarker for therapeutic purpose. Based on that, the present study aims to critically analyze the immunopathological mechanisms of the microRNA let-7 in the infection caused by SARS-CoV-2.","PeriodicalId":55599,"journal":{"name":"Immuno-Analyse & Biologie Specialisee","volume":"127 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89205615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Immune Dynamics Involved in Acute and Convalescent COVID-19 Patients COVID-19急性和恢复期患者的免疫动力学研究

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-03-17 DOI: 10.3390/immuno3010007

A. Silva-Junior, Lucas da Silva Oliveira, Nara Caroline Toledo Belezia, A. Tarragô, A. G. Costa, Adriana Malheiro

{"title":"Immune Dynamics Involved in Acute and Convalescent COVID-19 Patients","authors":"A. Silva-Junior, Lucas da Silva Oliveira, Nara Caroline Toledo Belezia, A. Tarragô, A. G. Costa, Adriana Malheiro","doi":"10.3390/immuno3010007","DOIUrl":"https://doi.org/10.3390/immuno3010007","url":null,"abstract":"COVID-19 is a viral disease that has caused millions of deaths around the world since 2020. Many strategies have been developed to manage patients in critical conditions; however, comprehension of the immune system is a key factor in viral clearance, tissue repairment, and adaptive immunity stimulus. Participation of immunity has been identified as a major factor, along with biomarkers, prediction of clinical outcomes, and antibody production after infection. Immune cells have been proposed not only as a hallmark of severity, but also as a predictor of clinical outcomes, while dynamics of inflammatory molecules can also induce worse consequences for acute patients. For convalescent patients, mild disease was related to higher antibody production, although the factors related to the specific antibodies based on a diversity of antigens were not clear. COVID-19 was explored over time; however, the study of immunological predictors of outcomes is still lacking discussion, especially in convalescent patients. Here, we propose a review using previously published studies to identify immunological markers of COVID-19 outcomes and their relation to antibody production to further contribute to the clinical and laboratorial management of patients.","PeriodicalId":55599,"journal":{"name":"Immuno-Analyse & Biologie Specialisee","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80912016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

The RadScopal Technique as an Immune Adjuvant to Treat Cancer 雷达内镜技术作为一种免疫佐剂治疗癌症

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-02-18 DOI: 10.3390/immuno3010006

H. Barsoumian, Jerry Hsu, Selene Nanez, Yun Hu, Ethan Y. Hsu, T. S. Riad, N. Puebla-Osorio, M. Angelica Cortez, J. W. Welsh

{"title":"The RadScopal Technique as an Immune Adjuvant to Treat Cancer","authors":"H. Barsoumian, Jerry Hsu, Selene Nanez, Yun Hu, Ethan Y. Hsu, T. S. Riad, N. Puebla-Osorio, M. Angelica Cortez, J. W. Welsh","doi":"10.3390/immuno3010006","DOIUrl":"https://doi.org/10.3390/immuno3010006","url":null,"abstract":"Since the momentous discovery of X-rays, high-dose radiotherapy (H-XRT) has been a cornerstone for combating cancer. The high-energy electromagnetic waves induce direct damage to tumor-cells’ DNA, thereby halting cell growth and proliferation, and eventually leading to tumor eradication. Furthermore, recent evidence suggests that H-XRT may have immunomodulatory properties which arise from its ability to induce the release of neoantigens, which in turn prime T-cells and contribute to T-cell repertoire diversity. Throughout the years, there have been different treatment modalities introduced as complements to H-XRT that have yielded greater results than monotherapy alone. In this review, we will discuss preclinical and clinical data related to the recently introduced low-dose radiotherapy (L-XRT) modality. We will also explore the justification for combining L-XRT and H-XRT, which became known as the “RadScopal Technique”, as a novel immune adjuvant to treat cancer. In this analysis, we detail and dissect the physiological mechanisms of action of each modality and describe the synergistic amalgamation effect observed on primary and metastatic tumors. Finally, we will explore the impetus for further studies to investigate combinations of the “RadScopal Technique” with various immune-oncology drug candidates.","PeriodicalId":55599,"journal":{"name":"Immuno-Analyse & Biologie Specialisee","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90963407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the Anti-Inflammatory Properties of Mastic Oil Extracted from Pistacia lentiscus var. chia 黄连木乳香油抗炎性能的评价

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-02-13 DOI: 10.3390/immuno3010005

K. Spyridopoulou, Georgios Aindelis, Georgia Kolezaki, A. Tiptiri-Kourpeti, K. Chlichlia

{"title":"Evaluation of the Anti-Inflammatory Properties of Mastic Oil Extracted from Pistacia lentiscus var. chia","authors":"K. Spyridopoulou, Georgios Aindelis, Georgia Kolezaki, A. Tiptiri-Kourpeti, K. Chlichlia","doi":"10.3390/immuno3010005","DOIUrl":"https://doi.org/10.3390/immuno3010005","url":null,"abstract":"Mastic oil (MO) is extracted from the resin of the bark of Pistacia lentiscus var. chia, a tree abundantly grown in the Greek island of Chios. Various biological activities, such as antimicrobial, anticancer and antioxidant, have been associated with the dietary intake of MO. However, little is known about MO’s potential anti-inflammatory effects, while some of its main chemical constituents were reported to exert significant anti-inflammatory activity. This study aims to assay the bioactivity of MO on in vitro and in vivo experimental inflammation models, in particular on LPS-stimulated RAW264.7 macrophages, murine primary peritoneal macrophages and a model of zymosan-induced peritonitis in BALB/c mice. The per os administration of MO inhibited the recruitment of macrophages into the peritoneal cavity of zymosan-treated mice, but did not affect neutrophil mobilisation or the levels of IL-6 or TNF-α in the peritoneal fluid. Similarly, IL-6 and TNF-α secretion in primary LPS-stimulated macrophages was not affected by MO, but the levels of phosphoproteins that activate inflammation in macrophages were differentially regulated. Finally, MO and some of its individual constituents reduced nitric oxide (NO), prostaglandin E2 and TNF-α levels in supernatants of LPS-stimulated RAW264.7 cells and inhibited their phagocytosis rate. Our data imply that MO may promote an anti-inflammatory transition in macrophages due to the combined bioactivities of its individual constituents. Thus, as a mixture of various compounds, MO seems to affect multiple molecular mechanisms that are involved in the development of inflammation. Therefore, more research, focusing on MO’s individual constituents and employing various pre-clinical inflammation models that activate different mechanisms, is required for a detailed investigation of the oil’s potential anti-inflammatory activity.","PeriodicalId":55599,"journal":{"name":"Immuno-Analyse & Biologie Specialisee","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84825358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combining CAR T Cell Therapy and Oncolytic Virotherapy for Pediatric Solid Tumors: A Promising Option 联合CAR - T细胞疗法和溶瘤病毒疗法治疗儿童实体瘤:一个有希望的选择

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-01-20 DOI: 10.3390/immuno3010004

Jianming He, Faryal Munir, D. Ragoonanan, W. Zaky, S. Khazal, P. Tewari, J. Fueyo, C. Gomez-Manzano, Hong Jiang

引用次数: 2

Acknowledgment to the Reviewers of Immuno in 2022 对《免疫》杂志2022年审稿人的感谢

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-01-16 DOI: 10.3390/immuno3010003

引用次数: 0

Plasma Cytokine Levels and Cytokine Genetic Polymorphisms in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy 接受大剂量化疗的转移性乳腺癌患者血浆细胞因子水平和细胞因子遗传多态性

Immuno-Analyse & Biologie Specialisee Pub Date : 2023-01-14 DOI: 10.3390/immuno3010002

R. Lafrenie, M. Bewick, Carly A. Buckner, M. Conlon

{"title":"Plasma Cytokine Levels and Cytokine Genetic Polymorphisms in Patients with Metastatic Breast Cancer Receiving High-Dose Chemotherapy","authors":"R. Lafrenie, M. Bewick, Carly A. Buckner, M. Conlon","doi":"10.3390/immuno3010002","DOIUrl":"https://doi.org/10.3390/immuno3010002","url":null,"abstract":"Differences in the baseline levels of serum cytokines or in single-nucleotide polymorphisms (SNPs) in cytokine genes may be useful to predict outcomes for patients being treated for metastatic breast cancer. We have measured the plasma levels and characterized individual SNPs for IL-1RA, IL-1b, IL-2, IL-6 and TNFa in 130 patients with metastatic breast cancer treated with high-dose chemotherapy. Patients were treated with high-dose cyclophosphamide (Group 1, 74 patients) or high-dose paclitaxel-containing regimens (Group 2, 56 patients). A high plasma level of IL-1RA and a SNP in the IL-1RA gene indicated a better prognosis for patients in Group 1 (but not Group 2). However, the level of plasma IL-1RA did not correlate with the SNP genotype. A high plasma level of IL-6 or TNFa indicated a poorer outcome for patients in Group 1 although the SNP genotypes for the IL-6 and TNFa SNPs were not associated with differences in outcome. The plasma levels of IL-1b and IL-2 and the genotype of the IL-1b SNPs did not indicate differences in outcome. Although, individually, plasma levels of cytokine or “risk” SNP genotypes may not indicate outcome, in combination there was an increased trend to predict outcome for patients treated with high-dose cyclophosphamide but not high-dose paclitaxel. These results suggest that the immune cytokines may be useful as prognostic biomarkers in the treatment of patients with metastatic breast cancer treated with different types of chemotherapy.","PeriodicalId":55599,"journal":{"name":"Immuno-Analyse & Biologie Specialisee","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90406353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune Modulatory Effects of Ketogenic Diet in Different Disease Conditions 生酮饮食在不同疾病条件下的免疫调节作用

Immuno-Analyse & Biologie Specialisee Pub Date : 2022-12-25 DOI: 10.3390/immuno3010001

Shivani Srivastava, V. Pawar, Anuradha Tyagi, K. Sharma, Vinay Kumar, S. Shukla

引用次数: 6

Uptake and Advanced Therapy of Butyrate in Inflammatory Bowel Disease 丁酸盐在炎症性肠病中的吸收和高级治疗

Immuno-Analyse & Biologie Specialisee Pub Date : 2022-11-25 DOI: 10.3390/immuno2040042

Shinji Ota, H. Sakuraba

{"title":"Uptake and Advanced Therapy of Butyrate in Inflammatory Bowel Disease","authors":"Shinji Ota, H. Sakuraba","doi":"10.3390/immuno2040042","DOIUrl":"https://doi.org/10.3390/immuno2040042","url":null,"abstract":"The pathogenesis and refractory nature of inflammatory bowel disease (IBD) are related to multiple factors, including genetic factors, environmental factors, and abnormalities in gut microbial diversity, which lead to decreased levels of short-chain fatty acids (SCFAs). Among SCFAs, butyrate plays an important role in mucosal barrier maintenance, serves as an energy source in intestinal epithelial cells (IECs), and exhibits anti-inflammatory effects; therefore, it is a particularly important factor in gut homeostasis. Changes in gut microbiota and butyrate levels affect the outcomes of drug therapy for IBD. Butyrate is mainly absorbed in the large intestine and is transported by monocarboxylate transporter 1 (MCT1) and sodium-coupled monocarboxylate transporter 1 (SMCT1). During gut inflammation, butyrate utilization and uptake are impaired in IECs. Dysbiosis and low abundance of butyrate affect fecal microbiota transplantation and anticancer immunotherapy. Although butyrate administration has been reported as a treatment for IBD, its effects remain controversial. In this review, we discuss butyrate absorption and metabolism in patients with IBD and their relationship with drug therapy.","PeriodicalId":55599,"journal":{"name":"Immuno-Analyse & Biologie Specialisee","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81123782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3